Akeso (9926.HK) announced that its first-in-class bispecific antibody, ivonescimab (PD-1/VEGF bispecific antibody), in combination with chemotherapy for first-line treatment of triple-negative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback